Merck KGaA · XETR:MRK
Merck KGaA — J.P. Morgan Healthcare Conference 2013
26 slides from Merck KGaA's conference presentation, Jan 7, 2013
Slide 1: Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany J.P. Morgan Healthcare Conference 2013 Matthias Zachert Stefan Oschmann Chief Financial Officer CEO Biopharmaceuticals San Francisco, January 7, 2013
Slide 2: Publication of Merck KGaA, Darmstadt, Germany
Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.
Slide 3: Disclaimer
Disclaimer Remarks All comparative figures relate to the corresponding last year’s period. Important information This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares referred to herein have not bee
Slide 4: Agenda
Agenda Business overview Transforming the company Biopharmaceuticals update
Slide 5: Balanced portfolio of four divisions
The Group Balanced portfolio of four divisions Divisional sales and operating profitability Margin1 Life Life Science Tools 20% 23.5% Biopharmaceuticals Science Tools 24% Performance Materials 23% 43.3% Consumer Health 12.7% 56% 16% Biopharmaceuticals 55% 28.8% Performance 4% Materials Consumer Heal
Slide 6: Geographically diverse business
The Group Geographically diverse business Sales by region [%] North America Europe 20% 37% 34% 9% Emerging Markets Rest of World* Strong presence in Emerging Markets * Africa, Australia, Japan Sales split based on YTD Sept 12 sales 6 5
Slide 7: We have added scale while strengthening the attractiveness of assets in our portfolio
The Group We have added scale while strengthening the attractiveness of assets in our portfolio 2002 Revenues €7.5 bn Transaction volume 2011 Revenues €10.3 bn Laboratory Millipore Life Science Tools Distribution Divestments Life Science Products Performance Materials Analytics & Reagents CropBiosci
Slide 8: Our stronger portfolio has enabled us to fundamentally improve our profitability
The Group Our stronger portfolio has enabled us to fundamentally improve our profitability Group total revenues and adjusted EBIT margin* 2002-2011 Acquisition of Millipore Acquisition of Serono adj. EBIT €m 10,276 margin* Divestment of Generics 10,000 9,291 7,747 30% 8,000 7,473 7,558 7,202 7,057 6
Slide 9: Agenda
Agenda Business overview Transforming the company Biopharmaceuticals update
Slide 10: Portfolio evolution improved our profitability structure, but further potential remains
Transforming the company Portfolio evolution improved our profitability structure, but further potential remains Assessment of long-term financial performance relative to peers Gross R&D Sales growth SG&A margin productivity Biopharmaceuticals Consumer Health Performance Materials Life Science Tools
Slide 11: We now focus on efficiency
Transforming the company We now focus on efficiency Transformation process 2012-2018 2012 2013 2014 2015 2016-18 Efficiency De-complex organization Optimize cost structure Increase R&D productivity Organic growth Exploit leading market positions Execute selected bolt-on acquisitions Portfo
Slide 12: New management in key positions and across the entire organization
Transforming the company New management in key positions and across the entire organization Management changes Divisions Biopharmaceuticals Corporate Head of Head of Biopharma- Head of Head of ceuticals Biopharma- Head of Consumer Life Science Corporate Chief Operating ceuticals Corporate HR Health
Slide 13: Restructuring costs and net savings targets
Transforming the company Restructuring costs and net savings targets Net annual savings [€m] 2012 2013 2014 2015 2016 2017 Total savings Biopharmaceuticals 50 200 300 300 Consumer Health 5 15 25 25 Life Science Tools 10 30 40 40 One-time costs [€m] Total savings of 2012 2013 2014 2015 € 365 million
Slide 14: 9M 2012: Execution drives solid numbers
Transformation shows first results 9M 2012: Execution drives solid numbers [€ m] 9M 2012 9M 2011 Δ Comments Sales 8,029 7,381 9% 9.0% sales growth reflects 4.1% organic growth, 4.3% EBITDA pre 2,175 2,043 6% FX benefit and 0.4% growth Margin (% of sales) 27.1% 27.7% from acquisitions EBITDA pre
Slide 15: Striving for realistic Group targets
The Group Striving for realistic Group targets Mid-term targets Sales (€m) EBITDA pre (€m) EPS pre (€) +4% - 8% +10% - 17% +20% - 32% 10,350 - 10,700 3,000 - 3,200 €8.20 - €9.00 9,906 2,729 €6.83 2011 2014E 2011 2014E 2011 2014E 27.5%* 29% – 30%* FX: EUR/USD = 1.35; EUR/CHF = 1.20 Assumptions
Slide 16: Agenda
Agenda Business overview Transforming the company Biopharmaceuticals update
Slide 17: Our business today
Biopharmaceuticals Our business today Geographic sales diversification Lack of patent cliff North America Europe provides resilient revenue stream 22% 42% Portfolio of strong 29% brands continue to 7% generate growth Rest of World Emerging Markets Rebuilding the pipeline to provide for future growth
Slide 18: Key products Rebif and Erbitux continue to be important assets
Biopharmaceuticals – Global franchises Key products Rebif and Erbitux continue to be important assets Global quarterly sales [€m] 492 499 430 A standard in current multiple sclerosis (MS) treatment Most prescribed MS treatment in many European markets 2011 Benefitting from positive pricing tre
Slide 19: Despite patent expiry many of our products continue to grow
Biopharmaceuticals – Global franchises Despite patent expiry many of our products continue to grow YTD Sept 12 global sales by franchise Fertility +15%* Endocrinology +12%* 53% 47% General Medicine flat* Rebif & Erbitux All other Biopharmaceuticals products Good franchises that continue to support t
Slide 20: Rebuilding our pipeline with an emphasis on phase I and II projects
Biopharmaceuticals – Pipeline Rebuilding our pipeline with an emphasis on phase I and II projects Phase I Phase II Phase III Dominated by phase III projects, using up large parts of the resources L-BLP25 (NSCLC) Cilengitide (GBM) Late-stage projects in non-core January ARX 201(GHD) Erbitux (aCC)
Slide 21: L-BLP25 (Stimuvax): phase III START trial
Biopharmaceuticals – Pipeline L-BLP25 (Stimuvax): phase III START trial L-BLP25: mode of action START trial did not meet primary endpoint of MUC1 antigen-specific prolongation of overall survival in patients with cancer immunotherapy Head-line unresectable, locally-advanced stage IIIA or IIIB re
Slide 22: TH-302: first-in-class potential in oncology
Biopharmaceuticals – Pipeline TH-302: first-in-class potential in oncology Proposed mode of action TH-302 Cell cycle Cancer cell Active drug (Prodrug) arrest death Oxygen-starved condition (e.g. tumor tissue) Phase III in soft tissue sarcoma (STS) Phase III in pancreatic cancer Global trial, 450 p
Slide 23: Upcoming pipeline newsflow
Biopharmaceuticals – Pipeline Upcoming pipeline newsflow Project Indication Current phase Timing Event Head-line result Cilengitide Glioblastoma Phase III H1 2013 (CENTRIC) TH-302 Soft tissue sarcoma Phase III H1 2013 Futility analysis Phase III ‘go/no go’ ONO-4641 Multiple sclerosis Phase II 2013 d
Slide 24: Alliance with Dr. Reddy's: entering growing biosimilars market
Biopharmaceuticals – Biosimilars Alliance with Dr. Reddy’s: entering growing biosimilars market Rationale: Biosimilars market is attractive Focus on monoclonal antibodies in oncology Co-development agreement of Merck KGaA, Darmstadt, Germany Experience in and Dr. Reddy’s + biosimilars Co-pro
Slide 25: Conclusion and mid-term targets
Biopharmaceuticals Conclusion and mid-term targets Targets Diversified business providing Sales [€m] EBITDA pre [€m] resilient revenue +2% - 6% +15% - 21% stream 5,700 - 5,900 1,800 - 1,900 New globalized 5.564 1.569 R&D organization to increase efficiency and success rate Rebuilding the pipeline
Slide 26: Merck KGaA
Merck KGaA Darmstadt - Germany